Giuseppe Cabibbo1, Alessandro Cucchetti2, Calogero Cammà1, Andrea Casadei-Gardini3, Ciro Celsa1, Giacomo Emanuele Maria Rizzo1, Philip Johnson4, Giorgio Ercolani2. 1. Section of Gastroenterology & Hepatology, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, University of Palermo, Palermo, Italy. 2. Department of Medical & Surgical Sciences - DIMEC; Alma Mater Studiorum - University of Bologna, Bologna, Italy. 3. Department of Medical and Surgical Sciences for Children and Adults, Division of Medical Oncology, Policlinico di Modena Azienda Ospedaliera - Universitaria di Modena, Modena, Italy. 4. Department of Molecular & Clinical Cancer Medicine, The Duncan Building, Daulby Street, University of Liverpool, Liverpool, UK.
Abstract
Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan-Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6-10.5), and median TTP was 4.1 months (95% CI: 3.8-4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-hepatic disease as predictors of longer OS. Conclusion: We provided a benchmark for future studies on sorafenib. The present results can be used in the decision making for the early shift to second-line strategy.
Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan-Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6-10.5), and median TTP was 4.1 months (95% CI: 3.8-4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-hepatic disease as predictors of longer OS. Conclusion: We provided a benchmark for future studies on sorafenib. The present results can be used in the decision making for the early shift to second-line strategy.
Entities:
Keywords:
hepatocellular carcinoma; meta-regression; sorafenib; survival; systemic therapy; time to progression
Authors: Ruwanthi Kolamunnage-Dona; Sarah Berhane; Harry Potts; Edward H Williams; James Tanner; Tobias Janowitz; Matthew Hoare; Philip Johnson Journal: J Hepatol Date: 2021-05-27 Impact factor: 30.083